|
|
533 Airport Boulevard, Suite 400
Burlingame, CA 94010 USA
phone:415-647-5639
fax:
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.nascentpharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Pharmaceutical candidates for oncology and women's health applications. |
|
| Management |
| Clive Reading, Chairman and Chief Executive Officer; Gene Barnett, Ph.D., Vice President, Regulatory/Clinical Affairs; Charles P.R. de C. du Me, Ph.D., Vice President, Development and Director |
|
|
| |
| Keywords |
| oncology, ophthalmology, preclinical, clinical, dry eye syndrome, postmenopausal, imaging agent |
|
|
|
|
|
| Description |
|
Nascent Pharmaceuticals, Inc. in-licenses potential pharmaceutical technologies, and performs pre-clinical and clinical development on promising candidates. |
|
| Products / Services |
Nascent has acquired technologies that are focused on oncology and women's health applications. These include: Topical therapeutics for dry eye syndrome in postmenopausal women, Oral nucleoside prodrug anti-cancer therapeutics, and Nucleoside cancer imaging agents.
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members